MiR-129-5p levels were decreased in mouse depression models. by Qiaozhen Qin (13159201)

“…The Y-axis represents the fold change, while the X-axis indicates the significance of differential expression. The gray points represent miRNAs with no significant change (p < 0.05, false discovery rate (FDR) q < 0.05), while red and blue points indicate upregulated and downregulated miRNAs (p < 0.05, FDR q < 0.05), respectively. …”

Elevated concentrations of serum MMA among participants with decreased cognitive performance. by Yige Liu (11940344)

Significantly Enriched Pathways. by Jiyong Zhang (2498740)

Mean ± SD values of unipedal stance parameters evaluated at the different time points of the postural training session. by Cristina Dolciotti (16317330)

Decreased virulence observed during <i>in planta</i> infection with <i>ΔFgknr4</i>. by Erika Kroll (20537020)

“…</b> Wheat spike infection assay done on the susceptible cultivar Bobwhite point inoculated with sterile water only (M), wild-type <i>F</i>. …”

Middle cerebral artery mean flow velocity at three time points. by Marco Carbonara (11483575)

Subjects:

Significantly decreased necrosis observed on wheat leaves inoculated with <i>ΔZtknr4</i>. by Erika Kroll (20537020)

PAP I point mutations lead to a decrease in pYV PCN, plasmid stability, and T3SS activity. by Katherine Schubert (5452712)

The mean and standard deviation of parameters. by Sadaf Sepasgozar Sarkhosh (20436143)

Subjects:

Transcriptome sequencing enriched sarcopenia related GO Biological process (BP) and Molecular function (MF). Enriched GO BP of DEGs. by Wenbin Wu (292223)

MWM training data. by Robert Botelho (20308297)

Subjects:

Spatial exploration patterns of tumor bearing mice under different treatment conditions in the Morris Water Maze (MWM). by Robert Botelho (20308297)

Subjects:

Spatial exploration patterns of non-tumor bearing mice under different treatment conditions in the Morris Water Maze (MWM). by Robert Botelho (20308297)

Subjects:

Summary of post-treatment disease course measures from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Study selection criteria. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications. by Filip Stanicic (17808254)

Subjects:

Disease course measures after the PTSD treatments. by Filip Stanicic (17808254)

Subjects:

PICOS criteria for the SLR. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment CAPS score changes from MDMA-AT publications. by Filip Stanicic (17808254)

Subjects:

Summary of post-treatment disease course measures from off-label medications clinical trials. by Filip Stanicic (17808254)

Subjects: